MIR494 (microRNA 494) - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: MIR494 (microRNA 494) Homo sapiens
Analyze
Symbol: MIR494
Name: microRNA 494
RGD ID: 1603770
HGNC Page HGNC:32084
Description: Enables mRNA base-pairing translational repressor activity. Involved in miRNA-mediated post-transcriptional gene silencing; negative regulation of cell migration involved in sprouting angiogenesis; and negative regulation of cell population proliferation. Located in extracellular vesicle. Implicated in cholangiocarcinoma; head and neck squamous cell carcinoma; osteosarcoma; pancreatic ductal adenocarcinoma; and urinary bladder cancer. Biomarker of several diseases, including acute kidney failure; cerebral infarction; gastrointestinal system cancer (multiple); pancreatic ductal adenocarcinoma; and toxic shock syndrome.
Type: ncrna (Ensembl: miRNA)
RefSeq Status: PROVISIONAL
Previously known as: hsa-mir-494; mir-494; MIRN494
RGD Orthologs
Mouse
Rat
Dog
Alliance Orthologs
More Info more info ...
Allele / Splice: See ClinVar data
Latest Assembly: GRCh38 - Human Genome Assembly GRCh38
Position:
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh3814101,029,634 - 101,029,714 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl14101,029,634 - 101,029,714 (+)EnsemblGRCh38hg38GRCh38
GRCh3714101,495,971 - 101,496,051 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 3614100,565,723 - 100,565,803 (+)NCBINCBI36Build 36hg18NCBI36
Celera1481,552,015 - 81,552,095 (+)NCBICelera
Cytogenetic Map14q32.31NCBI
HuRef1481,679,466 - 81,679,546 (+)NCBIHuRef
CHM1_114101,434,107 - 101,434,187 (+)NCBICHM1_1
T2T-CHM13v2.01495,265,090 - 95,265,170 (+)NCBIT2T-CHM13v2.0
JBrowse: View Region in Genome Browser (JBrowse)
Model


Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component

Molecular Function

References

References - curated
# Reference Title Reference Citation
1. Activation of microRNA-494-targeting Bmi1 and ADAM10 by silibinin ablates cancer stemness and predicts favourable prognostic value in head and neck squamous cell carcinomas. Chang YC, etal., Oncotarget. 2015 Sep 15;6(27):24002-16.
2. MicroRNA-494 is a master epigenetic regulator of multiple invasion-suppressor microRNAs by targeting ten eleven translocation 1 in invasive human hepatocellular carcinoma tumors. Chuang KH, etal., Hepatology. 2015 Aug;62(2):466-80. doi: 10.1002/hep.27816. Epub 2015 May 6.
3. MicroRNA-494 represses osteosarcoma development by modulating ASK-1 related apoptosis complexes. Gao G and Jian Y, Transl Cancer Res. 2020 Jul;9(7):4121-4130. doi: 10.21037/tcr-19-2195.
4. MicroRNA-494 targets PTEN and suppresses PI3K/AKT pathway to alleviate hypertrophic scar formation. He T, etal., J Mol Histol. 2019 Aug;50(4):315-323. doi: 10.1007/s10735-019-09828-w. Epub 2019 May 8.
5. MicroRNA-494 reduces ATF3 expression and promotes AKI. Lan YF, etal., J Am Soc Nephrol. 2012 Dec;23(12):2012-23. doi: 10.1681/ASN.2012050438. Epub 2012 Nov 15.
6. Intravenous antagomiR-494 lessens brain-infiltrating neutrophils by increasing HDAC2-mediated repression of multiple MMPs in experimental stroke. Li F, etal., FASEB J. 2020 May;34(5):6934-6949. doi: 10.1096/fj.201903127R. Epub 2020 Apr 2.
7. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells. Li L, etal., Gastroenterology. 2014 Aug;147(2):485-97.e18. doi: 10.1053/j.gastro.2014.04.048. Epub 2014 May 20.
8. MicroRNA-494-dependent WDHDI inhibition suppresses epithelial-mesenchymal transition, tumor growth and metastasis in cholangiocarcinoma. Liu B, etal., Dig Liver Dis. 2019 Mar;51(3):397-411. doi: 10.1016/j.dld.2018.08.021. Epub 2018 Aug 30.
9. TGF-β Enhances the Anti-inflammatory Effect of Tumor- Infiltrating CD33+11b+HLA-DR Myeloid-Derived Suppressor Cells in Gastric Cancer: A Possible Relation to MicroRNA-494. Moaaz M, etal., Asian Pac J Cancer Prev. 2020 Nov 1;21(11):3393-3403. doi: 10.31557/APJCP.2020.21.11.3393.
10. Overexpressed microRNA-494 represses RIPK1 to attenuate hippocampal neuron injury in epilepsy rats by inactivating the NF-κB signaling pathway. Qi Y, etal., Cell Cycle. 2020 Jun;19(11):1298-1313. doi: 10.1080/15384101.2020.1749472. Epub 2020 Apr 19.
11. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
12. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
13. Downregulation of MicroRNA-494 inhibits the TGF-β1/Smads signaling pathway and prevents the development of hypospadias through upregulating Nedd4L. Tian RH, etal., Exp Mol Pathol. 2020 Aug;115:104452. doi: 10.1016/j.yexmp.2020.104452. Epub 2020 May 13.
14. MicroRNA-494-3p alleviates inflammatory response in sepsis by targeting TLR6. Wang HF, etal., Eur Rev Med Pharmacol Sci. 2019 Apr;23(7):2971-2977. doi: 10.26355/eurrev_201904_17578.
15. MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. Wang X, etal., Circulation. 2010 Sep 28;122(13):1308-18. doi: 10.1161/CIRCULATIONAHA.110.964684. Epub 2010 Sep 13.
16. MicroRNA-494-3p protects rat cardiomyocytes against septic shock via PTEN. Wu P, etal., Exp Ther Med. 2019 Mar;17(3):1706-1716. doi: 10.3892/etm.2018.7116. Epub 2018 Dec 19.
17. MicroRNA-494-3p facilitates the progression of bladder cancer by mediating the KLF9/RGS2 axis. Xu XH, etal., Kaohsiung J Med Sci. 2022 Nov;38(11):1070-1079. doi: 10.1002/kjm2.12588. Epub 2022 Sep 13.
18. MicroRNA-494 promotes cyclosporine-induced nephrotoxicity and epithelial to mesenchymal transition by inhibiting PTEN. Yuan J, etal., Am J Transplant. 2015 Jun;15(6):1682-91. doi: 10.1111/ajt.13161. Epub 2015 Apr 6.
19. MicroRNA-494 inhibits breast cancer progression by directly targeting PAK1. Zhan MN, etal., Cell Death Dis. 2017 Jan 5;8(1):e2529. doi: 10.1038/cddis.2016.440.
20. Upregulation of miR-494 Inhibits Cell Growth and Invasion and Induces Cell Apoptosis by Targeting Cleft Lip and Palate Transmembrane 1-Like in Esophageal Squamous Cell Carcinoma. Zhang R, etal., Dig Dis Sci. 2015 May;60(5):1247-55. doi: 10.1007/s10620-014-3433-7. Epub 2014 Dec 6.
21. Silencing of microRNA-494 inhibits the neurotoxic Th1 shift via regulating HDAC2-STAT4 cascade in ischaemic stroke. Zhao H, etal., Br J Pharmacol. 2020 Jan;177(1):128-144. doi: 10.1111/bph.14852. Epub 2019 Nov 8.
22. Inhibited HDAC3 or Elevated MicroRNA-494-3p Plays a Protective Role in Myocardial Ischemia-Reperfusion Injury via Suppression of BRD4. Zheng W, etal., Mol Neurobiol. 2021 Sep;58(9):4268-4279. doi: 10.1007/s12035-021-02369-y. Epub 2021 May 12.
23. MicroRNA-494 improves functional recovery and inhibits apoptosis by modulating PTEN/AKT/mTOR pathway in rats after spinal cord injury. Zhu H, etal., Biomed Pharmacother. 2017 Aug;92:879-887. doi: 10.1016/j.biopha.2017.05.143. Epub 2017 Jun 7.
Additional References at PubMed
PMID:15965474   PMID:16274478   PMID:16381832   PMID:17604727   PMID:20807887   PMID:21037258   PMID:21809359   PMID:21859890   PMID:22028919   PMID:22042971   PMID:22151897   PMID:22785131  
PMID:22902743   PMID:23012423   PMID:23034410   PMID:23436935   PMID:23728345   PMID:23789915   PMID:23913442   PMID:24269020   PMID:24316134   PMID:24349514   PMID:24364919   PMID:24452363  
PMID:24612089   PMID:24644030   PMID:24928439   PMID:25085941   PMID:25111814   PMID:25226615   PMID:25270723   PMID:25277099   PMID:25500095   PMID:25653011   PMID:25660325   PMID:25662849  
PMID:25738254   PMID:25809707   PMID:25861022   PMID:25873402   PMID:25906693   PMID:25955111   PMID:25965392   PMID:26040900   PMID:26157120   PMID:26317788   PMID:26503214   PMID:26519878  
PMID:26686085   PMID:26718651   PMID:26782462   PMID:26794413   PMID:26908019   PMID:26999003   PMID:27149081   PMID:27181718   PMID:27399693   PMID:27696394   PMID:27722176   PMID:27980227  
PMID:27983981   PMID:28124060   PMID:28423484   PMID:28427186   PMID:28498442   PMID:28533480   PMID:28650977   PMID:28765880   PMID:28798470   PMID:28990071   PMID:29068478   PMID:29277888  
PMID:29286916   PMID:29304823   PMID:29305580   PMID:29567426   PMID:29786108   PMID:29956739   PMID:29992971   PMID:30234021   PMID:30261165   PMID:30365133   PMID:30381030   PMID:30431073  
PMID:30431102   PMID:30537730   PMID:30562741   PMID:30672438   PMID:30816202   PMID:30997877   PMID:31076630   PMID:31167152   PMID:31228937   PMID:31294463   PMID:31414754   PMID:31662984  
PMID:31686763   PMID:32132611   PMID:32240720   PMID:32353660   PMID:32372307   PMID:32419643   PMID:32420808   PMID:32985212   PMID:33129241   PMID:33435987   PMID:33461161   PMID:33462352  
PMID:33845753   PMID:34000275   PMID:34191748   PMID:34809740   PMID:34957935   PMID:35038704   PMID:35312115   PMID:35818261   PMID:35818268   PMID:35917658   PMID:36439870   PMID:36520055  
PMID:37163276   PMID:37278055   PMID:37603538   PMID:39016137  


Genomics

Comparative Map Data
MIR494
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh3814101,029,634 - 101,029,714 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl14101,029,634 - 101,029,714 (+)EnsemblGRCh38hg38GRCh38
GRCh3714101,495,971 - 101,496,051 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 3614100,565,723 - 100,565,803 (+)NCBINCBI36Build 36hg18NCBI36
Celera1481,552,015 - 81,552,095 (+)NCBICelera
Cytogenetic Map14q32.31NCBI
HuRef1481,679,466 - 81,679,546 (+)NCBIHuRef
CHM1_114101,434,107 - 101,434,187 (+)NCBICHM1_1
T2T-CHM13v2.01495,265,090 - 95,265,170 (+)NCBIT2T-CHM13v2.0
Mir494
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm3912109,681,752 - 109,681,836 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl12109,681,752 - 109,681,836 (+)EnsemblGRCm39 Ensembl
GRCm3812109,715,318 - 109,715,402 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl12109,715,318 - 109,715,402 (+)EnsemblGRCm38mm10GRCm38
MGSCv3712110,953,528 - 110,953,612 (+)NCBIGRCm37MGSCv37mm9NCBIm37
Celera12110,912,544 - 110,912,628 (+)NCBICelera
Cytogenetic Map12F1NCBI
cM Map1260.56NCBI
Mir494
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr86134,550,115 - 134,550,197 (+)NCBIGRCr8
mRatBN7.26128,728,710 - 128,728,792 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl6128,728,709 - 128,728,793 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx6128,907,952 - 128,908,034 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.06129,203,784 - 129,203,866 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.06128,565,401 - 128,565,483 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.06133,864,370 - 133,864,452 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl6133,864,369 - 133,864,453 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.06143,026,541 - 143,026,623 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Celera6126,313,091 - 126,313,173 (+)NCBICelera
Cytogenetic Map6q32NCBI
MIR494
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.1869,261,385 - 69,261,465 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl869,261,385 - 69,261,465 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha868,779,460 - 68,779,540 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0869,543,096 - 69,543,176 (+)NCBIROS_Cfam_1.0
UMICH_Zoey_3.1869,206,644 - 69,206,724 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0869,272,734 - 69,272,814 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0869,670,734 - 69,670,814 (+)NCBIUU_Cfam_GSD_1.0


Clinical Variants
Name Type Condition(s) Position(s) Clinical significance
GRCh38/hg38 14q32.2-32.33(chr14:99831655-106855263)x1 copy number loss See cases [RCV000133831] Chr14:99831655..106855263 [GRCh38]
Chr14:100297992..107263478 [GRCh37]
Chr14:99367745..106334523 [NCBI36]
Chr14:14q32.2-32.33
pathogenic
GRCh38/hg38 14q24.3-32.33(chr14:73655772-106879298)x3 copy number gain See cases [RCV000134000] Chr14:73655772..106879298 [GRCh38]
Chr14:74122475..107287505 [GRCh37]
Chr14:73192228..106358550 [NCBI36]
Chr14:14q24.3-32.33
pathogenic
GRCh38/hg38 14q32.2-32.33(chr14:100309382-105987610)x3 copy number gain See cases [RCV000135410] Chr14:100309382..105987610 [GRCh38]
Chr14:100775719..106453697 [GRCh37]
Chr14:99845472..105524742 [NCBI36]
Chr14:14q32.2-32.33
pathogenic
GRCh38/hg38 14q32.2-32.33(chr14:97638520-106855263)x3 copy number gain See cases [RCV000135400] Chr14:97638520..106855263 [GRCh38]
Chr14:98104857..107263478 [GRCh37]
Chr14:97174610..106334523 [NCBI36]
Chr14:14q32.2-32.33
pathogenic
GRCh38/hg38 14q32.2-32.33(chr14:99448012-106850609)x3 copy number gain See cases [RCV000135875] Chr14:99448012..106850609 [GRCh38]
Chr14:99914349..107258824 [GRCh37]
Chr14:98984102..106329869 [NCBI36]
Chr14:14q32.2-32.33
pathogenic
GRCh38/hg38 14q11.2-32.33(chr14:20151149-106855263)x3 copy number gain See cases [RCV000135543] Chr14:20151149..106855263 [GRCh38]
Chr14:20619308..107263478 [GRCh37]
Chr14:19689148..106334523 [NCBI36]
Chr14:14q11.2-32.33
pathogenic
GRCh38/hg38 14q32.12-32.33(chr14:92540983-104863658)x3 copy number gain See cases [RCV000135896] Chr14:92540983..104863658 [GRCh38]
Chr14:93007328..105329995 [GRCh37]
Chr14:92077081..104401040 [NCBI36]
Chr14:14q32.12-32.33
pathogenic
GRCh38/hg38 14q32.13-32.33(chr14:95524407-106879501)x1 copy number loss See cases [RCV000136032] Chr14:95524407..106879501 [GRCh38]
Chr14:95990744..107287708 [GRCh37]
Chr14:95060497..106358753 [NCBI36]
Chr14:14q32.13-32.33
pathogenic
GRCh38/hg38 14q24.3-32.33(chr14:77222795-106879298)x3 copy number gain See cases [RCV000138230] Chr14:77222795..106879298 [GRCh38]
Chr14:77689138..107287505 [GRCh37]
Chr14:76758891..106358550 [NCBI36]
Chr14:14q24.3-32.33
pathogenic
GRCh38/hg38 14q32.2-32.31(chr14:100262836-102500697)x1 copy number loss See cases [RCV000139723] Chr14:100262836..102500697 [GRCh38]
Chr14:100729173..102967034 [GRCh37]
Chr14:99798926..102036787 [NCBI36]
Chr14:14q32.2-32.31
pathogenic
GRCh38/hg38 14q11.2-32.33(chr14:20043514-106877229)x3 copy number gain See cases [RCV000143373] Chr14:20043514..106877229 [GRCh38]
Chr14:20511673..107285437 [GRCh37]
Chr14:19581513..106356482 [NCBI36]
Chr14:14q11.2-32.33
pathogenic
GRCh38/hg38 14q32.2-32.33(chr14:100582059-106877229)x1 copy number loss See cases [RCV000143662] Chr14:100582059..106877229 [GRCh38]
Chr14:101048396..107285437 [GRCh37]
Chr14:100118149..106356482 [NCBI36]
Chr14:14q32.2-32.33
pathogenic
NC_000014.9:g.100806482_101281031del474550 deletion Paternal uniparental disomy of chromosome 14 [RCV000149429] Chr14:100806482..101281031 [GRCh38]
Chr14:101272819..101747368 [GRCh37]
Chr14:14q32.2-32.31
pathogenic
GRCh38/hg38 14q32.2-32.33(chr14:100590353-106855264)x1 copy number loss Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000051553]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000051553]|See cases [RCV000051553] Chr14:100590353..106855264 [GRCh38]
Chr14:101056690..107263479 [GRCh37]
Chr14:100126443..106334524 [NCBI36]
Chr14:14q32.2-32.33
pathogenic
GRCh38/hg38 14q32.2-32.33(chr14:97938637-106855263)x1 copy number loss See cases [RCV000050696] Chr14:97938637..106855263 [GRCh38]
Chr14:98404974..107263478 [GRCh37]
Chr14:97474727..106334523 [NCBI36]
Chr14:14q32.2-32.33
pathogenic
GRCh38/hg38 14q32.2-32.33(chr14:100808300-106855263)x1 copy number loss See cases [RCV000051113] Chr14:100808300..106855263 [GRCh38]
Chr14:101274637..107263478 [GRCh37]
Chr14:100344390..106334523 [NCBI36]
Chr14:14q32.2-32.33
pathogenic
GRCh38/hg38 14q32.2-32.33(chr14:100309382-106855263)x1 copy number loss See cases [RCV000050938] Chr14:100309382..106855263 [GRCh38]
Chr14:100775719..107263478 [GRCh37]
Chr14:99845472..106334523 [NCBI36]
Chr14:14q32.2-32.33
pathogenic
GRCh38/hg38 14q31.2-32.33(chr14:83912345-106855405)x3 copy number gain See cases [RCV000052294] Chr14:83912345..106855405 [GRCh38]
Chr14:84378689..107263620 [GRCh37]
Chr14:83448442..106334665 [NCBI36]
Chr14:14q31.2-32.33
pathogenic
GRCh38/hg38 14q31.3-32.33(chr14:86094030-106832642)x3 copy number gain See cases [RCV000052295] Chr14:86094030..106832642 [GRCh38]
Chr14:86560374..107240869 [GRCh37]
Chr14:85630127..106311914 [NCBI36]
Chr14:14q31.3-32.33
pathogenic
GRCh38/hg38 14q32.12-32.33(chr14:91455861-106832642)x3 copy number gain See cases [RCV000052296] Chr14:91455861..106832642 [GRCh38]
Chr14:91922205..107240869 [GRCh37]
Chr14:90991958..106311914 [NCBI36]
Chr14:14q32.12-32.33
pathogenic
GRCh38/hg38 14q32.13-32.33(chr14:94628219-106451054)x3 copy number gain Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000052298]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000052298]|See cases [RCV000052298] Chr14:94628219..106451054 [GRCh38]
Chr14:95094556..106906960 [GRCh37]
Chr14:94164309..105978005 [NCBI36]
Chr14:14q32.13-32.33
pathogenic
miRNA Target Status

Confirmed Targets
Gene TargetMature miRNAMethod NameResult TypeData TypeSupport TypePMID
PTENhsa-miR-494-3pMirtarbaseexternal_infoqRT-PCR//Luciferase reporter assay//Western blotFunctional MTI20006626
PTENhsa-miR-494-3pMirtarbaseexternal_infoFlow//Luciferase reporter assay//Microarray//qRT-PFunctional MTI22544933
BMAL1hsa-miR-494-3pMirtarbaseexternal_infoLuciferase reporter assay//qRT-PCRFunctional MTI21799909
BCL2L11hsa-miR-494-3pMirtarbaseexternal_infoLuciferase reporter assay//qRT-PCR//Western blotFunctional MTI23012423
BCL2L11hsa-miR-494-3pOncomiRDBexternal_infoNANA23012423
PTTG1hsa-miR-494-3pOncomiRDBexternal_infoNANA22785131
IGF2BP1hsa-miR-494-3pOncomiRDBexternal_infoNANA22151897
KIThsa-miR-494-3pOncomiRDBexternal_infoNANA22042971
CDK6hsa-miR-494-3pOncomiRDBexternal_infoNANA21809359
BIRC5hsa-miR-494-3pOncomiRDBexternal_infoNANA20807887
PTENhsa-miR-494-5pMirecordsexternal_info{unchanged}NA20006626

Predicted Targets
Summary Value
Count of predictions:26949
Count of gene targets:10908
Count of transcripts:21195
Interacting mature miRNAs:hsa-miR-494-3p, hsa-miR-494-5p
Prediction methods:Microtar, Miranda, Pita, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


Expression

RNA-SEQ Expression

adipose tissue
alimentary part of gastrointestinal system
appendage
circulatory system
ectoderm
endocrine system
endoderm
entire extraembryonic component
exocrine system
hemolymphoid system
hepatobiliary system
integumental system
mesenchyme
mesoderm
musculoskeletal system
nervous system
renal system
reproductive system
respiratory system
sensory system
4 5 12 5 53 23 22 1 4 18 3 8 41 34 11 56 5 18 18 3

Sequence


Ensembl Acc Id: ENST00000349529
Type: CODING
Position:
Human AssemblyChrPosition (strand)Source
GRCh38.p14 Ensembl14101,029,634 - 101,029,714 (+)Ensembl
RefSeq Acc Id: NR_030174
RefSeq Status: PROVISIONAL
Type: NON-CODING
Position:
Human AssemblyChrPosition (strand)Source
GRCh3814101,029,634 - 101,029,714 (+)NCBI
GRCh3714101,495,971 - 101,496,051 (+)RGD
Celera1481,552,015 - 81,552,095 (+)RGD
HuRef1481,679,466 - 81,679,546 (+)ENTREZGENE
CHM1_114101,434,107 - 101,434,187 (+)NCBI
T2T-CHM13v2.01495,265,090 - 95,265,170 (+)NCBI
Sequence:

Additional Information

Database Acc Id Source(s)
AGR Gene HGNC:32084 AgrOrtholog
COSMIC MIR494 COSMIC
Ensembl Genes ENSG00000194717 Ensembl, ENTREZGENE
Ensembl Transcript ENST00000349529 ENTREZGENE
GTEx ENSG00000194717 GTEx
HGNC ID HGNC:32084 ENTREZGENE
Human Proteome Map MIR494 Human Proteome Map
miRBase MI0003134 ENTREZGENE
NCBI Gene 574452 ENTREZGENE
OMIM 616036 OMIM
PharmGKB PA164722740 PharmGKB
RNAcentral URS0000535FDD RNACentral
  URS00006A5ABA RNACentral
  URS000075CDF9 RNACentral